Cholesterol, LDL

• 

  Subject Areas on Research

  • 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. 
  • A classification system to evaluate weight maintainers, gainers, and losers. 
  • A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. 
  • A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. 
  • A note on sample size calculation for mean comparisons based on noncentral t-statistics. 
  • A protocol to evaluate the efficacy, perceptions, and cost of a cholesterol packaging approach to improve medication adherence. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. 
  • A telephone-delivered intervention for patients with NIDDM. Effect on coronary risk factors. 
  • A text messaging-assisted randomized lifestyle weight loss clinical trial among overweight adults in Beijing. 
  • A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. 
  • Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. 
  • Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. 
  • Acute coronary syndromes in deployed military personnel. 
  • Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. 
  • Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol. 
  • Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. 
  • Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). 
  • Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. 
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. 
  • An adverse lipoprotein phenotype-hypertriglyceridaemic hyperapolipoprotein B-and the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort study. 
  • An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. 
  • An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. 
  • Analytical performance and clinical utility of a direct LDL-cholesterol assay in a hyperlipidemic pediatric population. 
  • Angiographic changes in vein grafts: stable surrogate or seductive siren? 
  • Apheresis to Mitigate Atherosclerotic Vascular Disease. 
  • ApoB. 
  • Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. 
  • Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. 
  • Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. 
  • Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. 
  • Assessing the accuracy of a point-of-care analyzer for hyperlipidaemia in western Kenya. 
  • Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. 
  • Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. 
  • Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. 
  • Association of DASH diet with cardiovascular risk factors in youth with diabetes mellitus: the SEARCH for Diabetes in Youth study. 
  • Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. 
  • Association of lipid profile biomarkers with breast cancer by molecular subtype: analysis of the MEND study. 
  • Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. 
  • Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. 
  • Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. 
  • Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. 
  • Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. 
  • Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. 
  • Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. 
  • Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients. 
  • Beneficial effects of pinacidil on blood lipids: comparisons with prazosin and placebo in patients with hypertension. Pinacidil-Prazosin and Pinacidil-Placebo Research Groups, Lilly Research Laboratories. 
  • Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Beverage Consumption and Longitudinal Changes in Lipoprotein Concentrations and Incident Dyslipidemia in US Adults: The Framingham Heart Study. 
  • Biological, clinical and population relevance of 95 loci for blood lipids. 
  • Caffeine and cholesterol: interactions with hostility. 
  • Can group medical clinics improve lipid management in diabetes? 
  • Cardio-metabolic risk factors and prehypertension in persons without diabetes, hypertension, and cardiovascular disease. 
  • Cardiovascular Disease Prevention: Pharmacologic Prevention. 
  • Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. 
  • Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country. 
  • Causal effects of cardiovascular risk factors on onset of major age-related diseases: A time-to-event Mendelian randomization study. 
  • Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon). 
  • Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. 
  • Cholesterol and cognitive performance among community volunteers from the Czech Republic. 
  • Cholesterol curves to identify population norms by age and sex in healthy weight children. 
  • Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. 
  • Cholesterol rethink for high-risk patients. 
  • Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. 
  • Clinical reasoning and prevention of cardiovascular disease. 
  • Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. 
  • Combination lipid therapy: could teamwork make the dream work? 
  • Combined association of lipids and blood pressure in relation to incident cardiovascular disease in the elderly: the cardiovascular health study. 
  • Common variants associated with plasma triglycerides and risk for coronary artery disease. 
  • Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. 
  • Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. 
  • Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. 
  • Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. 
  • Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. 
  • Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. 
  • Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. 
  • Deep thoughts on lipids and cognition. 
  • Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. 
  • Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. 
  • Dietary fish oil. Influence on lesion regression in the porcine model of atherosclerosis. 
  • Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. 
  • Discovery and refinement of loci associated with lipid levels. 
  • Does a high level of HDL-C cholesterol undo the bad effects of a high LDL-C cholesterol? 
  • Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. 
  • Dyslipidaemia and microvascular disease in the retina. 
  • Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. 
  • Effect of Alirocumab on Mortality After Acute Coronary Syndromes. 
  • Effect of actinomycin D on serum betalipoproteins of partially hepatectomized dogs. I. Proteins, lipids, triglycerides and cholesterol. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. 
  • Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. 
  • Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). 
  • Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. 
  • Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. 
  • Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. 
  • Effects of aerobic training with and without weight loss on insulin sensitivity and lipids. 
  • Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. 
  • Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). 
  • Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. 
  • Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. 
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 
  • Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. 
  • Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. 
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 
  • Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. 
  • Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. 
  • Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. 
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. 
  • Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. 
  • Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. 
  • Endothelial dysfunction in chronic inflammatory diseases. 
  • Enteric microbiome metabolites correlate with response to simvastatin treatment. 
  • Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs. 
  • Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. 
  • Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. 
  • Evaluation and clinical application of a direct low-density lipoprotein cholesterol assay in normolipidemic and hyperlipidemic adults. 
  • Evaluation of a packaging approach to improve cholesterol medication adherence. 
  • Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. 
  • Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. 
  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 
  • Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I. 
  • Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. 
  • Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. 
  • Extended-release niacin for modifying the lipoprotein profile. 
  • Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. 
  • Extracellular lipid deposition in atherosclerosis. 
  • Extreme elevations of low-density lipoprotein cholesterol with very low carbohydrate, high fat diets. 
  • Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 
  • Ezetimibe plus a Statin after Acute Coronary Syndromes. 
  • Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. 
  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. 
  • Fine mapping of a linkage peak with integration of lipid traits identifies novel coronary artery disease genes on chromosome 5. 
  • From the editor: Confronting a pandemic or two. 
  • Genetic interactions drive heterogeneity in causal variant effect sizes for gene expression and complex traits. 
  • Genetically determined height and coronary artery disease. 
  • Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. 
  • Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. 
  • Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. 
  • Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. 
  • Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. 
  • Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. 
  • HEMOGLOBIN A1C, BLOOD PRESSURE, AND LDL-CHOLESTEROL CONTROL AMONG HISPANIC/LATINO ADULTS WITH DIABETES: RESULTS FROM THE HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL). 
  • Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. 
  • Heart matters: Gender and racial differences cardiovascular disease risk factor control among veterans. 
  • Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. 
  • Heterozygous ABCG5 Gene Deficiency and Risk of Coronary Artery Disease. 
  • High-dose atorvastatin after stroke or transient ischemic attack. 
  • Hypercholesterolemia and prostate cancer: a hospital-based case-control study. 
  • Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. 
  • Hypolipidemic activity of boronated nucleosides and nucleotides in rodents. 
  • Identification and quantification of regioisomeric cholesteryl linoleate hydroperoxides in oxidized human low density lipoprotein and high density lipoprotein. 
  • Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. 
  • Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease. 
  • Impact of Secondary Prevention in an Occupational High-Risk Group. 
  • Impact of lipid-lowering medications and low-density lipoprotein levels on 1-year clinical outcomes after coronary artery bypass grafting. 
  • Impact of psychological stress on the associations between apolipoprotein E variants and metabolic traits: findings in an American sample of caregivers and controls. 
  • Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. 
  • In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. 
  • Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. 
  • Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. 
  • Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. 
  • Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants: A Cohort Study. 
  • Is nuclear magnetic resonance lipoprotein subclass related to diabetic retinopathy? The multi-ethnic study of atherosclerosis (MESA). 
  • LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA. 
  • Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. 
  • Lifetime risk for developing dyslipidemia: the Framingham Offspring Study. 
  • Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk. 
  • Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. 
  • Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). 
  • Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. 
  • Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. 
  • Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease. 
  • Lipids in high-risk patients presenting with ischemic stroke or transient ischemic attack: are we missing the target? 
  • Lipoprotein response to exercise training and a low-fat diet in older subjects with glucose intolerance. 
  • Lipoprotein(a) Testing Patterns in a Large Health System. 
  • Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. 
  • Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. 
  • Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. 
  • Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. 
  • Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. 
  • Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. 
  • Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. 
  • Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. 
  • Lovastatin and coadministered antihypertensive/cardiovascular agents. 
  • Lovastatin increases exercise-induced skeletal muscle injury. 
  • Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. 
  • Low LDL cholesterol, statins, and brain hemorrhage: should we worry? 
  • Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. 
  • Low-density lipoprotein cholesterol level and statin use among Medicare beneficiaries with diabetes mellitus. 
  • Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. 
  • Low-density lipoprotein cholesterol was inversely associated with 3-year all-cause mortality among Chinese oldest old: data from the Chinese Longitudinal Healthy Longevity Survey. 
  • Marginal vitamin B-6 deficiency decreases plasma (n-3) and (n-6) PUFA concentrations in healthy men and women. 
  • Mechanisms of patient health behavior change in a randomized controlled trial of a spouse-assisted intervention. 
  • Mediation of the APOE associations with Alzheimer's and coronary heart diseases through body mass index and lipids. 
  • Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. 
  • Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. 
  • Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. 
  • Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. 
  • Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. 
  • Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. 
  • Night shift work and cardiovascular disease biomarkers in female nurses. 
  • Nurse practitioner management of type 2 diabetes. 
  • On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). 
  • Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. 
  • PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection. 
  • PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. 
  • PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites. 
  • PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. 
  • Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. 
  • Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. 
  • Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. 
  • PheProb: probabilistic phenotyping using diagnosis codes to improve power for genetic association studies. 
  • Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. 
  • Platelet reactivity and thrombogenicity in postmenopausal women. 
  • Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. 
  • Polymorphisms at newly identified lipid-associated loci are associated with blood lipids and cardiovascular disease in an Asian Malay population. 
  • Premature release of data from clinical trials of ezetimibe. 
  • Prevalence and risk factors of retinal arteriolar emboli: the Singapore Malay Eye Study. 
  • Prevalence of age-related macular degeneration in a Malay population: the Singapore Malay Eye Study. 
  • Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Primary care provider type: Are there differences in patients' intermediate diabetes outcomes? 
  • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. 
  • Quantifying Importance of Major Risk Factors for Coronary Heart Disease. 
  • Quantitative and Qualitative Role of Antagonistic Heterogeneity in Genetics of Blood Lipids. 
  • Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. 
  • Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). 
  • Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C. 
  • Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. 
  • Reduction of atherogenic risk factors by short-term weight reduction. Evidence of the efficacy of National Cholesterol Education Program guidelines for the obese. 
  • Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. 
  • Relations of trait depression and anxiety to low lipid and lipoprotein concentrations in healthy young adult women. 
  • Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. 
  • Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? 
  • Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond. 
  • Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". 
  • Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease". 
  • Results and Lessons of a Pilot Study of Cascade Screening for Familial Hypercholesterolemia in US Primary Care Practices. 
  • Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals. 
  • Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. 
  • Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. 
  • SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. 
  • Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). 
  • Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. 
  • Secondary prevention risk interventions via telemedicine and tailored patient education (SPRITE): a randomized trial to improve postmyocardial infarction management. 
  • Serum Cholesterol Levels within the High Normal Range Are Associated with Better Cognitive Performance among Chinese Elderly. 
  • Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). 
  • Statins for stroke prevention. 
  • Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. 
  • Study protocol: Couples Partnering for Lipid Enhancing Strategies (CouPLES) - a randomized, controlled trial. 
  • Study protocol: the Adherence and Intensification of Medications (AIM) study--a cluster randomized controlled effectiveness study. 
  • Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. 
  • Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study. 
  • The 1p13.3 LDL (C)-associated locus shows large effect sizes in young populations. 
  • The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines. 
  • The Cholesterol, Hypertension, and Glucose Education (CHANGE) study for African Americans with diabetes: study design and methodology. 
  • The LDL cholesterol in stroke limbo: how low can we go? 
  • The adaptor protein beta-arrestin2 enhances endocytosis of the low density lipoprotein receptor. 
  • The association between triglycerides and incident cardiovascular disease: What is "optimal"? 
  • The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study. 
  • The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. 
  • The complex relationship between cholesterol and brain hemorrhage. 
  • The effect of a hypertension self-management intervention on diabetes and cholesterol control. 
  • The effect of a nurse-led telephone-based care coordination program on the follow-up and control of cardiovascular risk factors in patients with coronary artery disease. 
  • The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. 
  • The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. 
  • The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder. 
  • The influence of statin medications on prostate-specific antigen levels. 
  • The relationship between albuminuria and hypercholesterolemia. 
  • The trials and tribulations of enrolling couples in a randomized, controlled trial: a self-management program for hyperlipidemia as a model. 
  • The use of lipid-lowering drugs in children. 
  • Therapy and clinical trials. 
  • To condition or not condition? Analysing 'change' in longitudinal randomised controlled trials. 
  • Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. 
  • Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. 
  • Transitions from Ideal to Intermediate Cholesterol Levels may vary by Cholesterol Metric. 
  • Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? 
  • Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. 
  • Treatment of type III hyperlipoproteinemia. 
  • Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. 
  • Trends in cardiovascular risk factors and treatment goals in patients with diabetes in Singapore-analysis of the SingHealth Diabetes Registry. 
  • U.S.S.R. and U.S. nutrient intake, plasma lipids, and lipoproteins in men ages 40-59 sampled from Lipid Research Clinics populations. 
  • US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. 
  • Universal Cholesterol Screening in Childhood: A Systematic Review. 
  • Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). 
  • Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). 
  • Whole genome sequence analysis of blood lipid levels in >66,000 individuals. 
  • Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. 
• 

  Keywords of People

  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Olsen, Maren Karine, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine